374620-70-9
374620-70-9
Chemical Structure
NBI-31772
- CAS No.: 374620-70-9
- Formula:C17H11NO7
- Molecular Weight:341.27
IUPAC Name: 1-(3,4-dihydroxybenzoyl)-6,7-dihydroxyisoquinoline-3-carboxylic acid
InChIKey: ZCMFEWUYBFMLIN-UHFFFAOYSA-N
SMILES: O=C(C1=CC(O)=C(O)C=C1)C2=NC(C(O)=O)=CC3=C2C=C(O)C(O)=C3
Biological Activity: NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NBI-31772 | 98.88% | NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NBI-31772 (Standard) | ≥98% | NBI-31772 (Standard) is the analytical standard of NBI-31772. This product is intended for research and analytical applications. NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Khawaja XZ. Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening. Anal Biochem. 2007;366(1):80-86. [Content Brief]
- [2]. Mackay K B, et al. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo[J]. Journal of Cerebral Blood Flow & Metabolism, 2003, 23(10): 1160-1167. [Content Brief]
- [3]. De Ceuninck F, et al. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes[J]. Arthritis Res Ther, 2004, 6: 1-11. [Content Brief]
- [4]. Li J, et al. Insulin-like growth factor binding proteins inhibit oocyte maturation of zebrafish[J]. General and Comparative Endocrinology, 2019, 281: 83-90. [Content Brief]
